Market Failure and the Lack of New Drugs for Maternal Health
Author Information
Author(s): Nicholas M. Fisk, Rifat Atun
Primary Institution: Imperial College London
Hypothesis
Have the market models for pharmaceuticals in developed countries and international mechanisms failed to address the needs of maternal health?
Conclusion
The study concludes that there is a significant under-investment in maternal health drugs, with only one new class licensed in the last 20 years.
Supporting Evidence
- Only 17 drugs are under active development for maternal health, which is less than 3% of the pipeline in cardiovascular health.
- Only one new class of drug has been licensed for obstetric conditions in the last 20 years.
- 99% of maternal deaths occur in developing countries, often due to preventable conditions.
Takeaway
There aren't enough new medicines being developed for pregnant women, which is a big problem because many women and babies need better treatments.
Methodology
The study involved a search of the Pharmaprojects database to track drugs under development for maternal health and compared this with other therapeutic areas.
Potential Biases
The reliance on off-label drug use and the lack of clinical trials for pregnant women may introduce bias in treatment safety and efficacy.
Limitations
The study may have missed some agents due to the limitations of the database and search methods used.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website